You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Iressa

Showing 1 - 25 of 263
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ovarian Cancer, Peritoneal Tumors, Fallopian Tube Cancer Trial in Houston (Topotecan, Gefitinib)

Completed
Has Results
  • Ovarian Cancer
  • +2 more
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Jan 11, 2022

Non-small Cell Lung Carcinoma Trial (Pembrolizumab, Paclitaxel, Carboplatin)

Completed
Has Results
  • Non-small Cell Lung Carcinoma
  • Pembrolizumab
  • +7 more
  • (no location specified)
Oct 13, 2022

Lung Cancer Trial in Boston (EGF816, Gefitinib)

Active, not recruiting
  • Lung Cancer
  • Boston, Massachusetts
    Massachusetts General Hospital
Jan 21, 2022

NSCLC Trial in Singapore (Gefitinib)

Completed
  • Non-small Cell Lung Cancer
  • Singapore, Singapore
    National Cancer Centre
May 31, 2021

Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma Trial in Philadelphia (drug, radiation, other)

Completed
  • Adult Giant Cell Glioblastoma
  • +2 more
  • Philadelphia, Pennsylvania
    Radiation Therapy Oncology Group
Oct 29, 2020

Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer Trial in Worldwide (Pharmacokinetic

Active, not recruiting
Has Results
  • Advanced Non Small Cell Lung Cancer
  • Advanced (Inoperable) Non Small Cell Lung Cancer
  • Pharmacokinetic sampling
  • +2 more
  • San Diego, California
  • +15 more
Feb 21, 2022

NSCLC With EGFR-Activating Mutations Trial in Worldwide (Dacomitinib (PF-00299804), Gefitinib)

Completed
Has Results
  • Non-small Cell Lung Cancer With EGFR-Activating Mutations
  • Beijing, China
  • +51 more
Feb 10, 2022

Bevacizumab Plus EGFR-TKIs in Chinese EGFR-mutant

Recruiting
  • NSCLC
  • Guangzhou, Guangdong, China
    Guangdong Provincial People's Hospital
Oct 17, 2020

Head Neck Cancer Trial in Chicago (ZD 1839 500mg)

Completed
Has Results
  • Head and Neck Cancer
  • ZD 1839 500mg
  • Chicago, Illinois
    The University of Chicago Medical Center
May 18, 2020

NSCLC Trial in Worldwide (Gefitinib, Placebo, Pemetrexed)

Completed
Has Results
  • Non-Small Cell Lung Cancer
  • Beijing, China
  • +60 more
Sep 24, 2020

NSCLC, EGFR Gene Mutation, Brain Metastases Trial in Worldwide (AZD3759, Erlotinib, Gefitinib)

Completed
  • Non-small Cell Lung Cancer
  • +2 more
  • Hefei, Anhui, China
  • +57 more
Nov 18, 2022

NSCLC Trial in Worldwide (Lazertinib 240 mg/160 mg, Gefitinib 250 mg, Lazertinib-matching 240 mg/160 mg)

Active, not recruiting
  • Non-Small Cell Lung Cancer
  • Lazertinib 240 mg/160 mg
  • +3 more
  • Woolloongabba, Queensland, Australia
  • +79 more
Nov 1, 2022

NSCLC Trial in Worldwide (Osimertinib, Savolitinib, Gefitinib)

Recruiting
  • Non-Small Cell Lung Cancer
  • Duarte, California
  • +52 more
Jan 19, 2023

NSCLC Trial in Worldwide (Osimertinib, Gefitinib)

Active, not recruiting
  • NSCLC
  • Bordeaux, France
  • +21 more
Mar 5, 2021

Prostate Cancer Trial in Calgary, Toronto (gefitinib)

Completed
  • Prostate Cancer
  • Calgary, Alberta, Canada
  • +1 more
Apr 2, 2020

NSCLC Trial in Guangzhou (Volitinib, gefitinib)

Completed
  • Non-Small Cell Lung Cancer
  • Guangzhou, China
    Guangdong General Hospital
Apr 20, 2020

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer Trial in Worldwide (AZD9291 80

Active, not recruiting
Has Results
  • Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
  • AZD9291 80 mg/40 mg + placebo
  • +5 more
  • Anaheim, California
  • +168 more
Nov 29, 2022

NSCLC, EGFR Gene Mutation Trial in Nanchang (Gefitinib, Anlotinib)

Unknown status
  • Non-small Cell Lung Cancer
  • EGFR Gene Mutation
  • Nanchang, Jiangxi, China
    The Second Afiliated Hospital of Nanchang University
Apr 21, 2020

Non Small Cell Lung Cancer Trial in Nanjing (Gefitinib)

Completed
  • Non Small Cell Lung Cancer
  • Nanjing, Jiangsu, China
    Nanjing General Hospital of Nanjing Military Command
Feb 5, 2020

Liver Cancer Trial in Singapore (Gefetinib (Iressa))

Unknown status
  • Liver Cancer
  • Gefetinib (Iressa)
  • Singapore, Singapore
    Tan Tock Seng Hospital
Apr 11, 2019

Bladder Cancer Trial in Canada (biological, drug, procedure)

Terminated
  • Bladder Cancer
  • BCG vaccine
  • +2 more
  • Vancouver, British Columbia, Canada
  • +5 more
Apr 1, 2020

Lung Cancer, Nonsmall Cell Trial in Guangzhou (Gefitinib, Anlotinib Hydrochloride, Placebo)

Unknown status
  • Lung Cancer, Nonsmall Cell
  • Guangzhou, Guangdong, China
    Cancer Center of Sun Yat-Sen University (CCSU)
Nov 7, 2019

NSCLC Trial in Shanghai, Hangzhou (Fruquintinib, Gefitinib)

Completed
  • NSCLC
  • Shanghai, Shanghai, China
  • +1 more
Nov 14, 2019

Recurrent Uterine Corpus Carcinoma Trial in Philadelphia (Gefitinib, Laboratory Biomarker Analysis)

Completed
  • Recurrent Uterine Corpus Carcinoma
  • Philadelphia, Pennsylvania
    Gynecologic Oncology Group
Jul 22, 2019

Cancer Trial (gefitinib, Yiqi-yangyin-jiedu decoction, )

Unknown status
  • Cancer
  • (no location specified)
Apr 10, 2019